Constipation
Conditions
Brief summary
This study evaluates the addition of naloxegol (Movantik) to a laxative protocol in critically ill adults requiring scheduled opioid (e.g. fentanyl) therapy. Half of the participants will receive naloxegol and a laxative protocol and half the participants will receive a placebo and a laxative protocol.
Detailed description
Among the more than 5 million adults who are admitted to the ICU each year in the USA, most have pain and thus receive a pain (analgesic) medication called an opioid. Opioid use in critically ill adults continues to increase given the greater awareness of untreated pain in the ICU and that an opioid-first approach be used to optimize patient safety and comfort and improve tolerance with breathing machines (i.e. mechanical ventilation). Similar to constipation, paralysis of the lower gastrointestinal (GI) tract is defined as the inability to pass stool due to impaired gut movement, and is a common effect of opioid use in the critically ill. Lower GI tract paralysis may lead to nausea, vomiting, aspiration, compromise the ability to administer tube feeds (enteral nutrition), an increase abdominal pain, delirium and delay getting off mechanical ventilation. One recent randomized study found that aggressive use of laxatives to prevent lower GI tract paralysis in critically ill adults was associated with lower daily organ dysfunction \[as measured by the Sequential Organ Failure Assessment (SOFA) score\]. The lower GI tract paralysis that occurs in the critically ill often responds poorly to laxative medication therapy (e.g., senna, bisacodyl, lactulose). While stool softener medications like docusate are routinely administered to patients on opioids, laxative-based protocols are frequently not initiated in the ICU until signs of lower GI tract paralysis start to appear. There is therefore an important and unmet need for a safe and efficacious medication to prevent lower GI tract paralysis in critically ill adults who are initiated on opioid therapy. Naloxegol (Movantik) is a naloxone-like drug that blocks the effect of opioids on the opioid µ receptor in the gut but is not absorbed in the brain (and therefore does not block the pain effects of opioids). Naloxegol is currently approved by the Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in non-ICU patients receiving scheduled moderate to high dose opioids for the treatment of chronic non-cancer pain. Naloxegol has a mechanism of action, efficacy, convenience of administration, and safety profile that make it an ideal candidate for use as a preventative medication for lower GI tract paralysis in critically ill adults receiving scheduled opioid therapy. The investigators propose a pilot study in which they will test the hypothesis that naloxegol (versus placebo) will reduce the time to the first spontaneous bowel movement (SBM) that an ICU patient has, that it will prevent lower GI tract paralysis in critically ill adults initiated on scheduled IV opioid therapy, and its use will not result in side effects that are concerning to doctors or patients. The investigators will randomize 36 critically ill ICU patients (18 in each arm) to receive naloxegol \[25mg or 12.5mg (in patients with a creatinine clearance ≤ 60ml/min)\] or placebo. This pilot study will provide valuable information to help guide future, larger studies evaluating the role of naloxegol in critically ill adults.
Interventions
DRUGNaloxegol Oral Tablet
Naloxegol Oral Tablet 25 mg (or 12.5 mg) po (enteral) daily
DRUGPlacebo Oral Tablet
Placebo Oral Tablet po (enteral) twice daily
DRUGDocusate Sodium 100 Mg oral capsule [Colace]
Docusate Sodium 100 mg po (enteral) twice daily
DRUGSenna 217 Mg Oral Tablet
Senna 127 mg oral tablet daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=6 days after scheduled opioid initiation.
Polyethylene Glycols 17 g daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to 34 g daily if no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation.
DRUGBisacodyl 10 mg Suppository
Insert one suppository if no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation.
DRUGMagnesium Citrate Oral Liquid Product
Administer one 10 oz bottle if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation.
DRUGMethylnaltrexone
Administer 8 mg or 16 mg (depending on subject's weight) subcutaneously x 1 if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation, consult surgery/gastroenterology and discontinue study medication.
Sponsors
Tufts Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Admitted to an ICU * Expected to require admission to an ICU for ≥ 48 hours * Intravenous opioid administration in the prior 24 hours of ≥ 100 mcg fentanyl equivalents
Exclusion criteria
* Scheduled use of an opioid ≥ 10 mg morphine equivalents per day in the week prior to ICU admission * History of constipation (≤ 2 SBM per week and current use of stool softener or laxative therapy) prior to ICU admission * Current scheduled use of a medication affecting gastric motility * Current use of a medication known to be a strong CYP3A4 inhibitor * History of a neurologic condition that may affect the permeability of the blood-brain barrier * Acute GI condition (e.g., clinical evidence of acute fecal impaction/complete obstruction, acute surgical abdomen, acute GI bleeding) * Condition affecting GI motility or function (e.g. inflammatory bowel disease requiring immunosuppressive therapy, symptomatic Clostridium difficile, active diverticular disease, surgery on the colon or abdomen within 60 days of ICU admission) * Current use of total parenteral nutrition * Administration of enteral nutrition through a jejunal tube * Severe hepatic dysfunction * Endstage renal disease defined as either i. calculated creatinine clearance ≤ 10ml/min or ii. Any current use of renal replacement therapy * Inability to enroll in study and initiate study medication within 48 hours of the patient begin first initiated on scheduled IV opioid therapy after ICU admission * Unreliable method for enteral, gastric and/or oral medication administration (e.g., no feeding tube, nasogastric tube is on suction) * Current or previous use of an opioid antagonist agent (e.g., naloxegol, methylnaltrexone) in the past 30 days * Pregnant or actively lactating females * Current participation in another interventional clinical study * Inability to obtain informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to First Spontaneous Bowel Movement (SBM) Administration | First occurrence after study randomization during period of ICU admission or a maximum of 10 ICU days | Time to first spontaneous bowel movement during ICU admission after randomization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ICU Days Without a SBM | During period of ICU admission or a maximum of 10 ICU days | Measured ICU days that subjects did not have a SBM |
| Occurrence of Lower GI Tract Paralysis (≥3 Days Without a SBM) | From randomization to ICU discharge or a maximum of 10 ICU days | Measurement is the number of subjects in each group having this occurrence of lower GI tract paralysis during time frame |
| Average Daily Opioid Requirement [in IV Fentanyl Equivalents (mcg Per Day)] | From randomization to ICU discharge or a maximum of 10 ICU days | Average daily opioid requirement is converted to IV fentanyl equivalent listed in mcg per day |
| Number of Patients With Loose and Unformed or Liquid SBM | From randomization to ICU discharge or a maximum of 10 ICU days | Consistency of SBM is characterized in one of 4 categories: hard and formed, soft but formed, loose and unformed, and liquid. The number listed in the results section is the number of patients who had either loose or liquid SBM (as opposed to hard or soft formed). |
| Number of Patients That Required Use of the Study Laxative Protocol | From randomization to ICU discharge or a maximum of 10 ICU days | A 4-step laxative protocol was initiated when there was no spontaneous bowel movement greater than or equal to 3 days time. Data collected on study laxative protocol included any use as well as the highest level needed. |
| Percentage of Daily Goal Reached for Enteral Nutrition Administration | From randomization to ICU discharge or a maximum of 10 ICU days | Enteral nutrition is assessed as daily volume in mL and the reported measure is the percentage of daily goal of enteral nutrition met. |
| Daily Fluid Balance | From randomization to ICU discharge or a maximum of 10 ICU days | Daily fluid balance measured in mL is the 24 hours ins and outs |
| Time to First Spontaneous Bowel Movement (SBM) | First occurrence after initiation of IV opioid therapy during period of ICU admission or a maximum of 10 ICU days | Time to first spontaneous bowel movement during the ICU admission after opioid initiation |
| Daily Maximal Sedation Assessment Scale (SAS) Score | From randomization to ICU discharge or a maximum of 10 ICU days | The Sedation Assessment Scale is rated 1 to 7. Score of 7 is dangerous agitation. Score of 1 is unarousable. Score of 2 is very sedated. The presence of coma is based on the every 4 hour sedation agitation score scale (SAS) assessment. A score of 1 or 2 any time during the day represents that a coma is present. A score of 3-7 represents a subject with no coma present. Results listed here is days without coma (SAS score of 3-7) |
| Daily Presence of Delirium Using the Intensive Care Delirium Screening Checklist (ICDSC) | From randomization to ICU discharge or a maximum of 10 ICU days | Measures as days without delirium with daily presence of delirium assessed using the Intensive Care Delirium Screening Checklist (ICDSC) |
| Occurrence of Lower GI Tract Paralysis Requiring GI/Surgical Consultation | From randomization to ICU discharge or a maximum of 10 ICU days | Number of patients with GI tract paralysis requiring Gastroenterology service or Surgical service consultation |
| Days Without Mechanical Ventilation Support for Duration of ICU Stay | From ICU admission to ICU discharge or a maximum of 10 ICU days | Measure is days without mechanical ventilation for duration of ICU stay as expressed as median and inter-Quartile Range |
| Abdominal Pressure Measurement | From randomization to ICU discharge (or removal of foley catheter) or a maximum of 10 ICU days | On days when the patient had a urinary catheter in place for clinical reasons, a bladder pressure transducer was inserted and abdominal pressure was measured. The average daily maximum pressure score for each group is reported. |
| Time to First Episode of Diarrhea | Study drug initiation to first episode of diarrhea in hours. | The number of patients in each group with \> or equal to 1 episode of diarrhea after initiation of study drug. The time to first episode of diarrhea was measured in hours. |
| Daily Difference in the Pre-dose and Post-dose Clinical Opioid Withdrawal Scale (COWS) Score | One hour before the daily study drug administration and 2 hours after the daily study drug administration | Patients were evaluated 1 hour before and 2 hours after the administration of each dose of study medication using the Clinical Opioid Withdrawal Scale (COWS). COWS is used to help determine the stage or severity of opiate withdrawal and assess the level of physical dependence on opioids. The COWS score ranges from 0-36+. A score of 0 is no active opioid withdrawal. A score of 5-12 is mild; 13-24 is moderate; 25-36 is moderately severe and more than 36 is severe opioid withdrawal. |
| Daily Maximal Pain Scale Score | From randomization to ICU discharge or a maximum of 10 ICU days | Based on the highest daily Visual Analogue Scale-10 or Clinical Pain Observation tool assessment. VAS-10 is Visual Analogue Scale which uses a nurse-administered 10 point rating scale. A measurement of 0-1 is minimal pain. A measurement of 10 is severe pain. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Naloxegol Oral Tablet Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following:
1. Adverse event potentially attributable to the study drug.
2. Use of Relistor.
3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.
4. The participant has been administered 10 days of study medication.
5. The participant is discharged from the ICU.
6. The participant requires the initiation of a strong CYP3A4 inhibitor medication.
Other Name: Movantik | 6 |
| Placebo Oral Tablet Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily \[that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)\] until one of the following:
1. Adverse event potentially attributable to the study drug.
2. Use of Relistor.
3. Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.
4. The participant has been administered 10 days of study medication.
5. The participant is discharged from the ICU.
6. The participant requires the initiation of a strong CYP3A4 inhibitor medication.
Other Name: AstraZeneca provided Movantik placebo | 6 |
| Total | 12 |
Baseline characteristics
| Characteristic | Naloxegol Oral Tablet | Placebo Oral Tablet | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 3 Participants | 5 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants | 3 Participants | 7 Participants |
| Age, Continuous | 51 years STANDARD_DEVIATION 23 | 64 years STANDARD_DEVIATION 11 | 57 years STANDARD_DEVIATION 18 |
| APACHE-II: Acute Physiology and Chronic Health Evaluation (version II) | 20 units on a scale STANDARD_DEVIATION 6 | 19 units on a scale STANDARD_DEVIATION 7 | 19.5 units on a scale STANDARD_DEVIATION 6.5 |
| BMI | 40 kg/m2 STANDARD_DEVIATION 13 | 35 kg/m2 STANDARD_DEVIATION 16 | 38 kg/m2 STANDARD_DEVIATION 14 |
| Hours in ICU before enrollment | 50 hours STANDARD_DEVIATION 21 | 44 hours STANDARD_DEVIATION 21 | 48 hours STANDARD_DEVIATION 22 |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Region of Enrollment United States | 6 participants | 6 participants | 12 participants |
| Sex: Female, Male Female | 3 Participants | 4 Participants | 7 Participants |
| Sex: Female, Male Male | 3 Participants | 2 Participants | 5 Participants |
| SOFA score: Sequential Organ Failure Assessment Score | 8 units on a scale STANDARD_DEVIATION 4 | 6 units on a scale STANDARD_DEVIATION 2 | 7 units on a scale STANDARD_DEVIATION 3 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 0 / 6 |
| other Total, other adverse events | 4 / 6 | 4 / 6 |
| serious Total, serious adverse events | 0 / 6 | 0 / 6 |
Outcome results
Primary
Time to First Spontaneous Bowel Movement (SBM) Administration
Time to first spontaneous bowel movement during ICU admission after randomization
Time frame: First occurrence after study randomization during period of ICU admission or a maximum of 10 ICU days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Naloxegol Oral Tablet | Time to First Spontaneous Bowel Movement (SBM) Administration | 41 hours | Standard Deviation 25 |
| Placebo Oral Tablet | Time to First Spontaneous Bowel Movement (SBM) Administration | 33 hours | Standard Deviation 25 |
Secondary
Abdominal Pressure Measurement
On days when the patient had a urinary catheter in place for clinical reasons, a bladder pressure transducer was inserted and abdominal pressure was measured. The average daily maximum pressure score for each group is reported.
Time frame: From randomization to ICU discharge (or removal of foley catheter) or a maximum of 10 ICU days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Naloxegol Oral Tablet | Abdominal Pressure Measurement | 10 mmHg | Standard Deviation 4 |
| Placebo Oral Tablet | Abdominal Pressure Measurement | 13 mmHg | Standard Deviation 5 |
Secondary
Average Daily Opioid Requirement [in IV Fentanyl Equivalents (mcg Per Day)]
Average daily opioid requirement is converted to IV fentanyl equivalent listed in mcg per day
Time frame: From randomization to ICU discharge or a maximum of 10 ICU days
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Naloxegol Oral Tablet | Average Daily Opioid Requirement [in IV Fentanyl Equivalents (mcg Per Day)] | 1420 mcg per day |
| Placebo Oral Tablet | Average Daily Opioid Requirement [in IV Fentanyl Equivalents (mcg Per Day)] | 1600 mcg per day |
Secondary
Daily Difference in the Pre-dose and Post-dose Clinical Opioid Withdrawal Scale (COWS) Score
Patients were evaluated 1 hour before and 2 hours after the administration of each dose of study medication using the Clinical Opioid Withdrawal Scale (COWS). COWS is used to help determine the stage or severity of opiate withdrawal and assess the level of physical dependence on opioids. The COWS score ranges from 0-36+. A score of 0 is no active opioid withdrawal. A score of 5-12 is mild; 13-24 is moderate; 25-36 is moderately severe and more than 36 is severe opioid withdrawal.
Time frame: One hour before the daily study drug administration and 2 hours after the daily study drug administration
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Naloxegol Oral Tablet | Daily Difference in the Pre-dose and Post-dose Clinical Opioid Withdrawal Scale (COWS) Score | -0.1 Difference of COWS score | Standard Deviation 1.3 |
| Placebo Oral Tablet | Daily Difference in the Pre-dose and Post-dose Clinical Opioid Withdrawal Scale (COWS) Score | 0.2 Difference of COWS score | Standard Deviation 1.3 |
Secondary
Daily Fluid Balance
Daily fluid balance measured in mL is the 24 hours ins and outs
Time frame: From randomization to ICU discharge or a maximum of 10 ICU days
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Naloxegol Oral Tablet | Daily Fluid Balance | -338 mL |
| Placebo Oral Tablet | Daily Fluid Balance | -210 mL |
Secondary
Daily Maximal Pain Scale Score
Based on the highest daily Visual Analogue Scale-10 or Clinical Pain Observation tool assessment. VAS-10 is Visual Analogue Scale which uses a nurse-administered 10 point rating scale. A measurement of 0-1 is minimal pain. A measurement of 10 is severe pain.
Time frame: From randomization to ICU discharge or a maximum of 10 ICU days
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Naloxegol Oral Tablet | Daily Maximal Pain Scale Score | 0 score on a scale |
| Placebo Oral Tablet | Daily Maximal Pain Scale Score | 0 score on a scale |
Secondary
Daily Maximal Sedation Assessment Scale (SAS) Score
The Sedation Assessment Scale is rated 1 to 7. Score of 7 is dangerous agitation. Score of 1 is unarousable. Score of 2 is very sedated. The presence of coma is based on the every 4 hour sedation agitation score scale (SAS) assessment. A score of 1 or 2 any time during the day represents that a coma is present. A score of 3-7 represents a subject with no coma present. Results listed here is days without coma (SAS score of 3-7)
Time frame: From randomization to ICU discharge or a maximum of 10 ICU days
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Naloxegol Oral Tablet | Daily Maximal Sedation Assessment Scale (SAS) Score | 3 days |
| Placebo Oral Tablet | Daily Maximal Sedation Assessment Scale (SAS) Score | 7 days |
Secondary
Daily Presence of Delirium Using the Intensive Care Delirium Screening Checklist (ICDSC)
Measures as days without delirium with daily presence of delirium assessed using the Intensive Care Delirium Screening Checklist (ICDSC)
Time frame: From randomization to ICU discharge or a maximum of 10 ICU days
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Naloxegol Oral Tablet | Daily Presence of Delirium Using the Intensive Care Delirium Screening Checklist (ICDSC) | 5 days without delirium |
| Placebo Oral Tablet | Daily Presence of Delirium Using the Intensive Care Delirium Screening Checklist (ICDSC) | 6 days without delirium |
Secondary
Days Without Mechanical Ventilation Support for Duration of ICU Stay
Measure is days without mechanical ventilation for duration of ICU stay as expressed as median and inter-Quartile Range
Time frame: From ICU admission to ICU discharge or a maximum of 10 ICU days
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Naloxegol Oral Tablet | Days Without Mechanical Ventilation Support for Duration of ICU Stay | 0.5 days |
| Placebo Oral Tablet | Days Without Mechanical Ventilation Support for Duration of ICU Stay | 1 days |
Secondary
ICU Days Without a SBM
Measured ICU days that subjects did not have a SBM
Time frame: During period of ICU admission or a maximum of 10 ICU days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Naloxegol Oral Tablet | ICU Days Without a SBM | 2 Days | Standard Deviation 3 |
| Placebo Oral Tablet | ICU Days Without a SBM | 2 Days | Standard Deviation 2 |
Secondary
Number of Patients That Required Use of the Study Laxative Protocol
A 4-step laxative protocol was initiated when there was no spontaneous bowel movement greater than or equal to 3 days time. Data collected on study laxative protocol included any use as well as the highest level needed.
Time frame: From randomization to ICU discharge or a maximum of 10 ICU days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Naloxegol Oral Tablet | Number of Patients That Required Use of the Study Laxative Protocol | 5 participants |
| Placebo Oral Tablet | Number of Patients That Required Use of the Study Laxative Protocol | 4 participants |
Secondary
Number of Patients With Loose and Unformed or Liquid SBM
Consistency of SBM is characterized in one of 4 categories: hard and formed, soft but formed, loose and unformed, and liquid. The number listed in the results section is the number of patients who had either loose or liquid SBM (as opposed to hard or soft formed).
Time frame: From randomization to ICU discharge or a maximum of 10 ICU days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Naloxegol Oral Tablet | Number of Patients With Loose and Unformed or Liquid SBM | 5 Participants |
| Placebo Oral Tablet | Number of Patients With Loose and Unformed or Liquid SBM | 6 Participants |
Secondary
Occurrence of Lower GI Tract Paralysis (≥3 Days Without a SBM)
Measurement is the number of subjects in each group having this occurrence of lower GI tract paralysis during time frame
Time frame: From randomization to ICU discharge or a maximum of 10 ICU days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Naloxegol Oral Tablet | Occurrence of Lower GI Tract Paralysis (≥3 Days Without a SBM) | 2 Participants |
| Placebo Oral Tablet | Occurrence of Lower GI Tract Paralysis (≥3 Days Without a SBM) | 3 Participants |
Secondary
Occurrence of Lower GI Tract Paralysis Requiring GI/Surgical Consultation
Number of patients with GI tract paralysis requiring Gastroenterology service or Surgical service consultation
Time frame: From randomization to ICU discharge or a maximum of 10 ICU days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Naloxegol Oral Tablet | Occurrence of Lower GI Tract Paralysis Requiring GI/Surgical Consultation | 0 Participants |
| Placebo Oral Tablet | Occurrence of Lower GI Tract Paralysis Requiring GI/Surgical Consultation | 0 Participants |
Secondary
Percentage of Daily Goal Reached for Enteral Nutrition Administration
Enteral nutrition is assessed as daily volume in mL and the reported measure is the percentage of daily goal of enteral nutrition met.
Time frame: From randomization to ICU discharge or a maximum of 10 ICU days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Naloxegol Oral Tablet | Percentage of Daily Goal Reached for Enteral Nutrition Administration | 54 percentage of daily goals met | Standard Deviation 34 |
| Placebo Oral Tablet | Percentage of Daily Goal Reached for Enteral Nutrition Administration | 51 percentage of daily goals met | Standard Deviation 29 |
Secondary
Time to First Episode of Diarrhea
The number of patients in each group with \> or equal to 1 episode of diarrhea after initiation of study drug. The time to first episode of diarrhea was measured in hours.
Time frame: Study drug initiation to first episode of diarrhea in hours.
Population: Number of patients in each group with \> or equal to 1 episode of diarrhea.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Naloxegol Oral Tablet | Time to First Episode of Diarrhea | 40 hours |
| Placebo Oral Tablet | Time to First Episode of Diarrhea | 109 hours |
Secondary
Time to First Spontaneous Bowel Movement (SBM)
Time to first spontaneous bowel movement during the ICU admission after opioid initiation
Time frame: First occurrence after initiation of IV opioid therapy during period of ICU admission or a maximum of 10 ICU days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Naloxegol Oral Tablet | Time to First Spontaneous Bowel Movement (SBM) | 52 hours | Standard Deviation 28 |
| Placebo Oral Tablet | Time to First Spontaneous Bowel Movement (SBM) | 49 hours | Standard Deviation 38 |